Frances A. Shepherd

Frances A. Shepherd

Auto-generated profile, based on publicly available information

Frances A. Shepherd

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2007 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
FSFrances A. Shepherd
Frances A. Shepherd
JCJohn Crowley
John Crowley
PHPaul Van Houtte
Paul Van Houtte
PPPieter E. Postmus
Pieter E. Postmus
DCDesmond Carney
Desmond Carney
PGPeter Goldstraw
Peter Goldstraw

10 June 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
FSFrances A. Shepherd
Frances A. Shepherd
CDCaroline Domerg
Caroline Domerg
PHPierre Hainaut
Pierre Hainaut
PJPasi A. Jänne
Pasi A. Jänne
JPJean-Pierre Pignon
Jean-Pierre Pignon
MTMing Tsao
Ming Tsao
Purpose: We undertook this analysis of KRAS mutation in four trials of adjuvant chemotherapy (ACT) versus observation (OBS) to clarify the prognostic/predictive roles of KRAS in non–small-cell lung cancer (NSCLC). Methods: KRAS mutation was determined in blinded fashion. Exploratory analyses were performed to characterize relationships between mutation status and subtype and survival outcomes using a multivariable Cox model. Results: Among 1,543 patients (763 OBS, 780 ACT), 300 had KRAS mutations (codon 12, n = 275; codon 13, n = 24; codon 14, n = 1). In OBS patients, there was no prognostic difference for overall survival for codon-12 (mutation v wild type [WT] hazard ratio [HR] = 1.04; 95% CI, 0.77 to 1.40) or codon-13 (HR = 1.01; 95% CI, 0.47 to 2.17) mutations. No significant benefit from ACT was observed for WT-KRAS (ACT v OBS HR = 0.89; 95% CI, 0.76 to 1.04; P = .15) or codon-12 mutations (HR = 0.95; 95% CI, 0.67 to 1.35; P = .77); with codon-13 mutations, ACT was deleterious (HR = 5.78; 95% CI, 2.06 to 16.2; P < .001; interaction P = .002). There was no prognostic effect for specific codon-12 amino acid substitution. The effect of ACT was variable among patients with codon-12 mutations: G12A or G12R (HR = 0.66; P = .48), G12C or G12V (HR = 0.94; P = .77) and G12D or G12S (HR = 1.39; P = .48; comparison of four HRs, including WT, interaction P = .76). OBS patients with KRAS-mutated tumors were more likely to develop second primary cancers (HR = 2.76, 95% CI, 1.34 to 5.70; P = .005) but not ACT patients (HR = 0.66; 95% CI, 0.25 to 1.75; P = .40; interaction, P = .02). Conclusion: KRAS mutation status is not significantly prognostic. The potential interaction in patients with codon-13 mutations requires validation. At this time, KRAS status cannot be recommended to select patients with NSCLC for ACT.

15 November 2002 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
FSFrances A. Shepherd
Frances A. Shepherd
GGGiuseppe Giaccone
Giuseppe Giaccone
LSLesley Seymour
Lesley Seymour
CDChanna Debruyne
Channa Debruyne
ABAndrea Bezjak
Andrea Bezjak
BZBenny Chung-Ying Zee
Benny Chung-Ying Zee
PURPOSE: Increased expression of metalloproteinases is associated with poor prognosis in small-cell lung cancer (SCLC). This trial was undertaken to determine whether adjuvant treatment with the metalloproteinase inhibitor marimastat could prolong survival in responding patients with SCLC after chemotherapy. PATIENTS AND METHODS: SCLC patients in complete or partial remission were eligible. They were stratified by radiotherapy (early, late, or none), stage (extensive or limited), response (complete or partial), and cooperative group (National Cancer Institute of Canada-Clinical Trials Group or European Organization for Research and Treatment of Cancer). They were randomized to receive marimastat 10 mg or placebo orally bid for up to 2 years. RESULTS: There were 532 eligible patients (266 marimastat and 266 placebo). Stage was limited for 279 patients (52%) and extensive for 253 (48%). Best response to induction therapy was complete remission for 176 patients (33%), partial remission for 341 (64%), and 15 patients (3%) had undergone surgical resection. The median time to progression for marimastat patients was 4.3 months compared with 4.4 months for placebo patients (P = .81). Median survivals for marimastat and placebo patients were 9.3 months and 9.7 months, respectively (P = .90) Toxicity was generally limited to musculoskeletal symptoms (18% grade 3/4 for marimastat). Dose modifications for musculoskeletal toxicity were required in 90 patients (33%) on the marimastat arm, and 87 (32%) permanently stopped marimastat because of toxicity. Patients on marimastat had significantly poorer quality of life at 3 and 6 months. CONCLUSION: Treatment with marimastat after induction therapy for SCLC did not result in improved survival and had a negative impact on quality of life.

1 August 2001 in Cancer
Verified
Journal Article
Closed access
PDF file
FSFrances A. Shepherd
Frances A. Shepherd
JDJanet Dancey
Janet Dancey
AAAndrew Arnold
Andrew Arnold
ANAlan Neville
Alan Neville
JRJames Rusthoven
James Rusthoven
EEElizabeth Eisenhauer
Elizabeth Eisenhauer

28 February 2010 in Lung Cancer
Verified
Journal Article
Closed access
PDF file
RMRavi J. Menezes
Ravi J. Menezes
HRHeidi C. Roberts
Heidi C. Roberts
NPNarinder S. Paul
Narinder S. Paul
MMMaureen McGregor
Maureen McGregor
TCTae Bong Chung
Tae Bong Chung
FSFrances A. Shepherd
Frances A. Shepherd

1 February 2009 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
HHHamed Al Husaini
Hamed Al Husaini
PWPaul Wheatley-Price
Paul Wheatley-Price
MCMark Clemons
Mark Clemons
FSFrances A. Shepherd
Frances A. Shepherd